Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus concurrent chemoradiotherapy for limited-stage small cell lung cancer
ChiCTR2100043184Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in small cell lung cancer (SCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Started Jan 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100043184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043184.